FrancophonIA/ELRC3.0 huggingface dataset:
English: Extensive limb swelling at the injection site, frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb *Nausea and Injection site haematoma occurred at a frequency of Uncommon in infants **Rash occurred at a frequency of Common in infants ***ADR identified post-marketing
Estonian: Üldised häired ja manustamiskoha reaktsioonid väga sage palavik turse süstekohas valu süstekohas punetus süstekohas väsimus sage süstekoha verevalum aeg-ajalt halb enesetunne süstekoha induratsioon süstekoha kihelus süstekoha kuumatunne süstekoha anesteesia Teadmata*** Jäseme ulatuslik turse süstekohas, millega sageli kaasneb ka punetus ja mis mõnikord haarab naaberliigeseid, või kogu süstitud jäseme turse.
English: Study MenACWY-TT-039(1)
Estonian: Uuring MenACWY-TT-039
English: Instructions for reconstitution of the vaccine with the solvent presented in pre-filled syringe
Estonian: Juhised vaktsiini manustamiskõlblikuks muutmiseks süstlisse pakitud lahustiga
English: Pfizer Luxembourg SARL,
Estonian: Slovenská republika Pfizer Luxembourg SARL, organizačná zložka
English: Study MenACWY-TT-040(2)
Estonian: Uuring MenACWY-TT-040
English: Pfizer BV Tel: +31 (0)10 406 43 01
Estonian: Tel: +31 (0)10 406 43 01
English: Nimenrix must be reconstituted by adding the entire content of the pre-filled syringe of solvent to the vial containing the powder.
Estonian: Nimenrixi manustamiskõlblikuks muutmiseks tuleb kogu süstlis olev lahustikogus lisada pulbrit sisaldavasse viaali.
English: • swelling, pain and redness where the injection is given.
Estonian: • paistetus, valu ja punetus süstekohas
English: Excipients:
Estonian: Lahusti:
English: Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal group A, C, W-135 and Y conjugate vaccine
Estonian: Nimenrix süstelahuse pulber ja lahusti süstlis Meningokoki serogruppide A, C, W-135 ja Y konjugeeritud vaktsiin
English: Powder in a vial (type I glass) with a stopper (butyl rubber) and solvent in a pre-filled syringe with a stopper (butyl rubber).
Estonian: Pulber (butüülkummist) korgiga (I tüüpi klaasist) viaalis ja lahusti (butüülkummist) korgiga süstlis, koos nõeltega või ilma.
English: N ≥8 (95% CI)
Estonian: Ajahetk N  8 (95% CI)
English: Nimenrix powder and solvent for solution for injection in ampoule Meningococcal group A, C, W-135 and Y conjugate vaccine
Estonian: Nimenrix süstelahuse pulber ja lahusti ampullis Meningokoki serogruppide A, C, W-135 ja Y konjugeeritud vaktsiin
English: Nimenrix must be reconstituted by adding the entire content of the ampoule of solvent to the vial containing the powder.
Estonian: Nimenrixi manustamiskõlblikuks muutmiseks tuleb kogu ampullis olev lahusti lisada pulbrit sisaldavasse viaali.
English: Nimenrix booster vaccination in subjects previously primed with a monovalent (MenC-CRM) or a quadrivalent conjugate meningococcal vaccine (MenACWY-TT) was studied in subjects from 12 months of age onwards who received a booster vaccination.
Estonian: Alates 12 kuu vanuste vanuserühma kuuluvatel osalejatel uuriti Nimenrixi revaktsineerimist, kes olid varem saanud monovalentset (MenC-CRM) või neljavalentset konjugeeritud meningokokivaktsiini (MenACWY-TT).
English: 100 vials: powder 100 ampoules: solvent 100 x 1 dose (0.5 ml)
Estonian: 100 viaali: pulber 100 ampulli: lahusti 100 x 1 annus (0,5 ml)
English: Mening ococcal Group
Estonian: Mening okokki de serogrupp
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS PRE-FILLED SYRINGE WITH SOLVENT
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL
English: Powder and solvent for solution for injection in ampoule
Estonian: Süstelahuse pulber ja lahusti ampullis
English: Nervous system disorders
Estonian: naatriumkloriid süstevesi
English: 1 year CSR Q1 2017 3 year CSR Q1 2019 5 year CSR Q1 2021
Estonian: 3 aasta uuringuaruanne 1. kvartalis 2019
English: This leaflet was last revised in {MM/YYYY} Other sources of information
Estonian: Infoleht on viimati uuendatud
English: Pfizer Luxembourg SARL
Estonian: Pfizer BV
English: How to store Nimenrix
Estonian: Kuidas Nimenrixi säilitada
English: Instructions for reconstitution of the vaccine with the solvent presented in ampoules
Estonian: Juhised vaktsiini manustamiskõlblikuks muutmiseks ampulli pakitud lahustiga
English: 10 vials: powder 10 ampoules: solvent 10 x 1 dose (0.5 ml)
Estonian: 10 viaali: pulber 10 ampulli: lahusti 10 x 1 annus (0,5 ml)
English: * rSBA testing performed at Public Health England (PHE) laboratories in UK ** hSBA tested at Neomed, Laval, Canada blood sampling performed 1 month post vaccination
Estonian: **hSBA-d testiti Neomedis Kanadas Lavalis.
English: Study MenACWYTT-035 (18-55 years)
Estonian: Uuring MenACWYTT-035
English: How Nimenrix is given
Estonian: Kuidas Nimenrixi manustatakse
English: Menin gococc al Group
Estonian: Menin gokok kide serogrupp
English: • rSBA titres ≥32 for initially seronegative subjects (i.e., pre-vaccination rSBA titre <8)
Estonian: • esmaselt seronegatiivsetel uuritavatel (s.t vaktsineerimiseelne rSBA tiiter <8) oli rSBA tiiter
English: • difficulty sleeping
Estonian: • magamisraskused
English: 1 vial: powder 1 ampoule: solvent 1 dose (0.5 ml)
Estonian: 1 viaal: pulber 1 ampull: lahusti 1 annus (0,5 ml)
English: titres ≥8 (Table 4).
Estonian: Tabel 8.
English: VR: vaccine response * tested at GSK laboratories Persistence of the immune response was evaluated up to 5 years after vaccination in adolescents primed in study MenACWY-TT-036 (Table 13).
Estonian: Immuunvastuse püsivust kuni 5 aastat pärast vaktsineerimist hinnati noorukitel, kellel esmane vaktsineerimine oli tehtud uuringu MenACWY-TT-036 raames (tabel 13).
English: Intercurrent illness
Estonian: Kaasuv haigus
English: Malaise
Estonian: Ajahet
English: 10 vials: powder 10 pre-filled syringes: solvent 10 x 1 dose (0.5 ml)
Estonian: 10 viaali: pulber 10 süstlit: lahusti 10 x 1 annus (0,5 ml)
English: Post dose 2(1)
Estonian: Pärast 1. annust Pärast 2. annust
English: Table 4: Bactericidal antibody responses (rSBA*) in toddlers aged 12-23 months Menin gococc al
Estonian: Bakteritsiidsete antikehade vastused (rSBA*) 12…23 kuu vanustel väikelastel Menin gokok kide serogr upp
English: Therefore tell the doctor or nurse if you or your child fainted with a previous injection.
Estonian: Kui teie või teie laps on mõne varasema süsti tegemisega seoses minestanud, siis rääkige sellest arstile või meditsiiniõele.
English: 1 vial: powder 1 pre-filled syringe: solvent 1 dose (0.5 ml)
Estonian: 1 viaal: pulber 1 süstel: lahusti 1 annus (0,5 ml)
English: Table 6: Bactericidal antibody responses (rSBA)* in toddlers aged 12-14 months Meningococcal
Estonian: Bakteritsiidsete antikehade vastused (rSBA*) 12…14 kuu vanustel väikelastel Meningokokkide serogrupp
English: If Nimenrix is co-administered with other vaccines, different injection sites should be used.
Estonian: Nimenrixi manustamisel koos teiste vaktsiinidega tuleb kasutada erinevaid süstekohti.
English: Table 7: Bactericidal antibody responses (hSBA)* in toddlers aged 12-14 months Meningococcal
Estonian: Bakteritsiidsete antikehade vastused (hSBA*) 12…14 kuu vanustel väikelastel Meningokokkide serogrupp
English: Skin and subcutaneous tissue disorders
Estonian: 5 mikrogrammi konjugeeritud teetanuse toksoidi kandjavalkudel
English: (1) blood sampling performed 42 to 56 days post vaccination (2) blood sampling performed 30 to 42 days post vaccination * tested at GSK laboratories
Estonian: Vereproov võeti 30 kuni 42 päeva pärast vaktsineerimist.
English: Pfizer Kft Tel: +36 1 488 3700
Estonian: Tel: +36 1 488 3700
English: MenC-CRM
Estonian: Nimenrix MenC-CRM-i vaktsiin
English: Nimenrix may not work as well if you are taking medicines that affect your immune system.
Estonian: Kui võtate immuunsüsteemi mõjutavaid ravimeid, ei pruugi Nimenrix nii hästi toimida.
English: Very common Fever Swelling at injection site Pain at injection site Redness at injection site Fatigue
Estonian: Psühhiaatrilised häired väga sage ärritatavus aeg-ajalt unetus nutmine
English: Table 5: Bactericidal antibody responses (hSBA*) in toddlers aged 12-23 months Meningococcal
Estonian: Bakteritsiidsete antikehade vastused (hBSA*) 12…23 kuu vanustel väikelastel Meningokokkide serogrupp
English: W-135 Nimenrix 354 100% Y Nimenrix 354 100%
Estonian: Nimenrix 354 MenC-CRM-i vaktsiin W-135 Nimenrix 354
English: A 594 C 691
Estonian: C 691
English: The analysis of immunogenicity was conducted on the ATP cohorts for immunogenicity.
Estonian: Immunogeensuse analüüs tehti immunogeensuse protokollikohastel (ATP) kohortidel.
English: Nimenrix is a vaccine which helps protect against infections caused by bacteria (germs) called “Neisseria meningitidis" types A, C, W-135 and Y. “Neisseria meningitidis" types A, C, W-135 and Y bacteria can cause serious illnesses such as:
Estonian: Mis ravim on Nimenrix ja milleks seda kasutatakse Nimenrix on vaktsiin, mis aitab kaitsta Neisseria meningitidis'e nimeliste bakterite (pisikute) serogruppide A, C, W-135 ja Y poolt põhjustatud nakkuste eest.
English: Meningococcal Group
Estonian: Meningokokkide serogrupp
English: Syringe cap
Estonian: LAHUSTIGA SÜSTEL
English: Meningo coccal Group
Estonian: Meningo kokkide serogrup
English: Study MenACWYTT-036 (11-17 years)
Estonian: Uuring MenACWYTT-036
English: organizačná zložka
Estonian: Manustamisviis
English: Musculoskeletal and connective tissue disorders
Estonian: Süstelahuse pulber ja lahusti süstlis
English: Sucrose
Estonian: Pfizer
English: • crying
Estonian: • uimasus
English: Contents of the pack and other information What Nimenrix contains
Estonian: Mida Nimenrix sisaldab
English: • feeling drowsy
Estonian: • lihasevalu
English: Nimenrix will only confer protection against Neisseria meningitidis group A, C, W-135 and Y. The vaccine will not protect against any other Neisseria meningitidis groups.
Estonian: Nimenrix annab kaitse ainult Neisseria meningitidis'e serogruppide A, C, W-135 ja Y vastu.
English: Further information can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/imatinib-actavis.
Estonian: Lisateave Imatinib Actavise kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/imatinib-actavis.
English: Imatinib Actavis is available as capsules (50, 100 and 400 mg) and tablets (100 and 400 mg).
Estonian: Imatinib Actavist turustatakse kapslitena (50, 100 ja 400 mg) ja tablettidena (100 ja 400 mg).
English: What measures are being taken to ensure the safe and effective use of Imatinib Actavis?
Estonian: Mis meetmed võetakse, et tagada Imatinib Actavise ohutu ja efektiivne kasutamine?
English: Imatinib Actavis (imatinib)
Estonian: Imatinib Actavis (imatiniib)
English: This means that some of their genes have re-arranged themselves to form a special chromosome called the Philadelphia chromosome.
Estonian: See tähendab, et osa nende geenidest on muundunud ning on moodustunud eriline kromosoom - Philadelphia kromosoom.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Imatinib Actavis has been shown to have comparable quality and to be bioequivalent to Glivec.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt ELi nõuetele on tõendatud Imatinib Actavise võrreldav kvaliteet ja bioekvivalentsus ravimiga Glivec.
English: Imatinib Actavis received a marketing authorisation valid throughout the EU for Imatinib Actavis on 17 April 2013.
Estonian: Imatinib Actavis on saanud müügiloa, mis kehtib kogu ELis, 17. aprillil 2013.
English: Therefore, the Agency's view was that, as for Glivec, the benefit of Imatinib Actavis outweighs the identified risk and it can be authorised for use in the EU.
Estonian: Seetõttu on amet arvamusel, et nagu ka Gliveci korral, ületab Imatinib Actavise kasulikkus sellega kaasnevad riskid ja seda võib kasutada ELis.
English: As for every medicine, the company provided studies on the quality of Imatinib Actavis.
Estonian: Nagu iga ravimi korral, esitas ettevõte Imatinib Actavise kvaliteedi uuringud.
English: These enzymes can be found in some receptors on cancer cells, including the receptors that are involved in stimulating the cells to divide uncontrollably.
Estonian: Neid ensüüme leidub vähiraku pinna teatud retseptorites, sh neis, mis osalevad rakkude vohamise stimuleerimises.
English: Side effects reported with Imatinib Actavis are carefully evaluated and any necessary action taken to protect patients.
Estonian: Imatinib Actavise kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Because Imatinib Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Imatinib Actavis on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This means that Imatinib Actavis contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Glivec.
Estonian: See tähendab, et Imatinib Actavis sisaldab sama toimeainet ja toimib samamoodi nagu võrdlusravim Glivec, millel juba on ELis müügiluba.
English: Imatinib Actavis is given by mouth with a meal and a large glass of water to reduce the risk of irritation of the stomach and gut.
Estonian: Imatinib Actavist manustatakse suu kaudu söögi ajal koos suure klaasitäie veega, et vähendada mao ja soole ärrituse riski.
English: As for all medicines, data on the use of Imatinib Actavis are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Imatinib Actavise kasutamise kohta pidevat järelevalvet.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imatinib Actavis have been included in the summary of product characteristics and the package leaflet.
Estonian: Imatinib Actavise ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Glivec, and do not need to be repeated for Imatinib Actavis.
Estonian: Võrdlusravimiga Glivec on juba tehtud toimeaine heakskiidetud kasutamisviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Imatinib Actavis korrata.
English: For more information about using Imatinib Actavis, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet ravimi Imatinib Actavis kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: What is Imatinib Actavis and what is it used for?
Estonian: Mis on Imatinib Actavis ja milleks seda kasutatakse?
English: It is also used in children in the ‘chronic phase' of the disease if it is not responding to interferon alfa (another medicine used to treat cancer), and in more advanced phases of the disease (‘accelerated phase' and ‘blast crisis').
Estonian: Seda kasutatakse lastel ka haiguse kroonilises faasis, kui ravi alfainterferooniga (samuti vähiravim) on ebaõnnestunud või kui haigus on süvenenud (aktseleratsioonifaasis või blastses kriisis).
English: By blocking these receptors, Imatinib Actavis helps to control and slow down cell division.
Estonian: Nende retseptorite blokeerimisega aitab Imatinib Actavis piirata rakkude jagunemist.
English: • myelodysplastic or myeloproliferative diseases (MD/MPD), a group of diseases in which the body produces large numbers of abnormal blood cells.
Estonian: • Müelodüsplastilised või müeloproliferatiivsed haigused (MD/MPD) - haiguste rühm, mille korral organismis tekib suurel hulgal ebanormaalseid vererakke.
English: This means that it blocks enzymes known as tyrosine kinases.
Estonian: See blokeerib teatud ensüümide (türosiinkinaasid) toime.
English: Imatinib Actavis is a ‘generic medicine'.
Estonian: Imatinib Actavis on geneeriline ravim.
English: Imatinib Actavis is a cancer medicine that contains the active substance imatinib.
Estonian: Imatinib Actavis on ravim, mis sisaldab toimeainena imatiniibi.
English: Imatinib Actavis is used to treat adults with DFSP that cannot be removed with surgery, and in adults who cannot have surgery when the cancer has returned after treatment or has spread to other parts of the body.
Estonian: Imatinib Actavist kasutatakse protuberantse dermatofibrosarkoomiga täiskasvanute raviks, kui sarkoomi ei saa kirurgiliselt eemaldada, kui kasvaja on pärast ravi taastekkinud või on siiretega (levinud organismis ka mujale).
English: Imatinib Actavis is used when the patients are ‘Philadelphia-chromosome positive' (Ph+).
Estonian: Imatinib Actavist kasutatakse Philadelphia-kromosoom-positiivsetel (Ph+) patsientidel.
English: • advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
Estonian: • Kaugelearenenud hüpereosinofiilia sündroom (HES) või krooniline eosinofiilne leukeemia (CEL)haigused, mille korral eosinofiilid (teatud leukotsüüdid) hakkavad takistamatult vohama.
English: Other information about Imatinib Actavis
Estonian: Muu teave Imatinib Actavise kohta
English: An overview of Imatinib Actavis and why it is authorised in the EU
Estonian: Ülevaade ravimist Imatinib Actavis ja ELis müügiloa väljastamise põhjendus
English: How is Imatinib Actavis used?
Estonian: Kuidas Imatinib Actavist kasutatakse?
English: • dermatofibrosarcoma protuberans (DFSP), a type of cancer (sarcoma) in which cells in the tissue beneath the skin divide uncontrollably.
Estonian: • Protuberantne dermatofibrosarkoom (DFSP) - vähiliik (sarkoom), mille korral nahaaluskoe rakud vohavad.
English: The medicine can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.
Estonian: Imatinib Actavis on retseptiravim ja ravi sellega peab alustama verevähiga patsientide ravis kogenud arst.
English: How has Imatinib Actavis been studied?
Estonian: Kuidas Imatinib Actavist uuriti?
English: Imatinib Actavis is used to treat adults with MD/MPD who have re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR);
Estonian: Imatinib Actavist kasutatakse müelodüsplastiliste või müeloproliferatiivsete haigustega täiskasvanute ravimiseks, kellel on trombotsüütide kasvuteguri retseptori (PDGFR) geen muundunud.
English: It is also used alone to treat adults with Ph+ ALL that has returned following previous treatment, or if other medicines are not working.
Estonian: Ravimit kasutatakse ainuravimina ka Philadelphia-kromosoom-positiivne akuutne lümfoblastse leukeemia raviks täiskasvanutel, kelle haigus on pärast varasemat ravi taastekkinud või kellel ei teki muude ravimitega ravivastust.
English: Imatinib Actavis is used to treat adults with HES or CEL who have a specific re-arrangement of two genes called FIP1L1 and PDGFRα;
Estonian: Actavist kasutatakse kaugelearenenud hüpereosinofiilse sündroomi või kroonilise eosinofiilleukeemiaga täiskasvanute ravimiseks, kellel on kaks geeni (FIP1L1 ja PDGFRα) teataval viisil muundunud.
English: The medicine is used in children who have been newly diagnosed with Ph+ CML and who cannot have a bone marrow transplant.
Estonian: Imatinib Actavist kasutatakse lastel, kellel on äsja diagnoositud Philadelphia kromosoomiga krooniline müeloidleukeemia (Ph+ CML) ja kellele ei saa siirata luuüdi.
English: Imatinib Actavis is also used in adults with Ph+ CML in blast crisis.
Estonian: Imatinib Actavist kasutatakse Philadelphia kromosoomiga kroonilise müeloidleukeemiaga (Ph+ CML) täiskasvanutel, kelle haigus on blastses kriisis.
English: Imatinib Actavis is used with other cancer medicines in adults and children who have been newly diagnosed with Ph+ ALL.
Estonian: Imatinib Actavist kasutatakse koos teiste vähiravimitega täiskasvanute ja laste raviks, kellel on äsja diagnoositud Philadelphiakromosoom-positiivne akuutne lümfoblastne leukeemia (Ph+ ALL).
English: How does Imatinib Actavis work?
Estonian: Kuidas Imatinib Actavis toimib?
English: What are the benefits and risks of Imatinib Actavis?
Estonian: Milles seisneb Imatinib Actavise kasulikkus ja mis riskid ravimiga kaasnevad?
English: The active substance in Imatinib Actavis, imatinib, is a protein-tyrosine-kinase inhibitor.
Estonian: Imatinib Actavise toimeaine imatiniib on proteiintürosiinkinaasiinhibiitor.
English: Component of a multipack, cannot be sold separately.
Estonian: Mitmikpakendi osa, ei saa müüa eraldi.
English: Other medicines or vaccines and Hexyon
Estonian: Muud ravimid või vaktsiinid ja Hexyon
English: Vaccination with Hexyon may need to be delayed until your child is better.
Estonian: Vaktsineerimist Hexyon'iga võib edasi lükata, kuni teie laps on paranenud.
English: At the end of this period, Hexyon should be used or discarded.
Estonian: Hexyon tuleb selle perioodi lõpuks ära kasutada või ära visata.
English: To make sure that Hexyon is suitable for your child, it is important to talk to your doctor or nurse if any of the points below apply to your child.
Estonian: Veendumaks, et Hexyon on teie lapsele sobiv, on oluline pidada nõu oma arsti või meditsiiniõega, kui mõni alljärgnevatest punktidest kehtib teie lapse kohta.
English: • As with any vaccine, Hexyon may not protect 100% of children who receive the vaccine.
Estonian: • Nagu kõigi vaktsiinide puhul, ei pruugi Hexyon'iga vaktsineerimine kaitsta 100% lastest.
English: Your doctor will advise you whether your child should have Hexyon.
Estonian: Teie arst nõustab teid, kas teie lapsele peaks manustama Hexyon't.
English: What Hexyon looks like and contents of the pack
Estonian: Kuidas Hexyon välja näeb ja pakendi sisu
English: Do not use Hexyon if your child:
Estonian: Hexyon't ei tohi kasutada juhul, kui teie lapsel:
English: † See section c c- Description of selected adverse reactions
Estonian: † Vaata lõik c c- Valitud kõrvaltoimete kirjeldus
English: • Hexyon will only help to prevent these diseases if they are caused by the bacteria or viruses targeted by the vaccine.
Estonian: • Hexyon aitab haiguseid ennetada ainult juhul, kui neid põhjustavad vaktsiini sihtmärgiks olevad bakterid või viirused.
English: If you forget one dose of Hexyon
Estonian: Kui te unustate Hexyon ühe annuse
English: What Hexyon is and what it is used for What you need to know before Hexyon is given to your child How to use Hexyon
Estonian: Mis ravim on Hexyon ja milleks seda kasutatakse Mida on vaja teada enne Hexyon manustamist teie lapsele Kuidas Hexyon't kasutada
English: Hexyon (DTaP-IPV-HB-Hib) is a vaccine used to protect against infectious diseases.
Estonian: Hexyon (DTaP-IPV-HB-Hib) on vaktsiin, mida kasutatakse kaitseks nakkushaiguste eest.
English: The safety and efficacy of Hexyon in infants less than 6 weeks of age have not been established.
Estonian: Hexyon'i ohutus ja efektiivsus väikelastel vanuses alla 6 nädala ei ole veel tõestatud.
English: Possible side effects Like all medicines, this vaccine can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka see vaktsiin põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: What Hexyon is and what it is used for
Estonian: Mis ravim on Hexyon ja milleks seda kasutatakse
English: The safety of Hexyon in children over 24 months of age has not been studied in clinical trials.
Estonian: Hexyon'i ohutust üle 24 kuu vanustel lastel ei ole kliinilistes uuringutes uuritud.
English: • Hexyon should not be mixed with other medicinal products.
Estonian: • Hexyon't ei tohi segada teiste ravimitega.
English: Contents of the pack and other information What Hexyon contains The active substances are per dose (0.5 ml)1: Diphtheria Toxoid not less than 20 IU2
Estonian: Pakendi sisu ja muu teave Mida Hexyon sisaldab Toimeained ühe annuse kohta (0,5 ml)1: Difteeria toksoid mitte vähem kui 20 RÜ2